These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26212562)

  • 1. Comparative Pharmacokinetics, Tissue Distribution, Excretion of Recombinant LiverTargeting Interferon with IFN α2b Administered Intramuscular in Rats.
    Wang J; Lu X; Jin X; Zeng W; Zhu J
    Curr Pharm Biotechnol; 2015 Jul; ():. PubMed ID: 26212562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Pharmacokinetics, Tissue Distribution, Excretion of Recombinant Liver-Targeting Interferon with IFN α2b Administered Intramuscular in Rats.
    Wang J; Lu X; Jin X; Zeng W; Zhu J
    Curr Pharm Biotechnol; 2015; 16(10):911-9. PubMed ID: 26278706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-level expression of a novel liver-targeting fusion interferon with preferred Escherichia coli codon preference and its anti-hepatitis B virus activity in vivo.
    Lu X; Wang J; Jin X; Zhu J
    BMC Biotechnol; 2015 Jun; 15():54. PubMed ID: 26063245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicologic evaluations of recombinant liver-targeting interferon IFN-CSP: Genotoxicity and tegenicratoity.
    Zeng W; Wu C; Wang J; Cao L; Jin X; Zhu J; Lu X
    Regul Toxicol Pharmacol; 2017 Oct; 89():13-19. PubMed ID: 28709686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of a novel liver-targeting fusion interferon by incorporation of a Plasmodium region I-plus peptide.
    Lu X; Jin X; Huang Y; Wang J; Shen J; Chu F; Mei H; Ma Y; Zhu J
    Biomed Res Int; 2014; 2014():261631. PubMed ID: 24575402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant interferon-alpha2b poly(lactic-co-glycolic acid) microspheres: pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration.
    Zhang YM; Yang F; Yang YQ; Song FL; Xu AL
    Acta Pharmacol Sin; 2008 Nov; 29(11):1370-5. PubMed ID: 18954532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Mechanism of a Novel Liver-targeting Interferon IFN-CSP Involves Liver Heparan Sulfate Proteoglycan.
    Lu X; Wang J; Jin X; Huang Y; Zeng W; Zhu J
    Curr Drug Deliv; 2016; 13(4):528-33. PubMed ID: 26310618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses.
    Zhao HL; Xue C; Wang Y; Sun B; Yao XQ; Liu ZM
    Eur J Pharm Biopharm; 2009 Jun; 72(2):405-11. PubMed ID: 19462475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alpha-induced apoptosis on rat preneoplastic liver is mediated by hepatocytic transforming growth factor beta(1).
    de Luján Alvarez M; Ronco MT; Ochoa JE; Monti JA; Carnovale CE; Pisani GB; Lugano MC; Carrillo MC
    Hepatology; 2004 Aug; 40(2):394-402. PubMed ID: 15368444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel glycosylated human interferon alpha 2b expressed in glycoengineered Pichia pastoris and its biological activity: N-linked glycoengineering approach.
    Katla S; Yoganand KNR; Hingane S; Ranjith Kumar CT; Anand B; Sivaprakasam S
    Enzyme Microb Technol; 2019 Sep; 128():49-58. PubMed ID: 31186110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
    ter Borg MJ; Hansen BE; Herrmann E; Zeuzem S; Cakaloglu Y; Karayalcin S; Flisiak R; van' t Veen A; de Man RA; Schalm SW; Janssen HL; Haagmans BL;
    Antivir Ther; 2007; 12(8):1285-94. PubMed ID: 18240868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients.
    Espinosa M; Arenas MD; Aumente MD; Barril G; Buades JM; Aviles B; Carretero D; Alvarez-Lara MA; Carnicer F; Martin-Malo A; Aljama P
    Clin Nephrol; 2007 Jun; 67(6):366-73. PubMed ID: 17598372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection.
    Ozgenc F; Dikici B; Targan S; Doganci T; Akman S; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Feb; 9(1):23-6. PubMed ID: 15040533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of bioactive liver-targeting interferon Mu-IFN-CSP by soluble prokaryotic expression.
    Liu A; Gui S; Zhang L; Chen Z; Tang Y; Xiao M; Wang J; Liu W; Jin X; Zhu J; Lu X
    AMB Express; 2017 Oct; 7(1):192. PubMed ID: 29086199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of interferon-alpha2b administration on rat liver regeneration after partial hepatectomy.
    Theocharis SE; Margeli AP; Skaltsas SD; Skopelitou AS; Mykoniatis MG; Kittas CN
    Dig Dis Sci; 1997 Sep; 42(9):1981-6. PubMed ID: 9331165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery.
    Yadav P; McLeod VM; Nowell CJ; Selby LI; Johnston APR; Kaminskas LM; Trevaskis NL
    J Control Release; 2018 Feb; 272():17-28. PubMed ID: 29305921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
    J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
    Flori N; Funakoshi N; Duny Y; Valats JC; Bismuth M; Christophorou D; Daurès JP; Blanc P
    Drugs; 2013 Mar; 73(3):263-77. PubMed ID: 23436591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.